The SARS-Cov-2 pandemic illustrates how variable vaccines can be in their length of efficacy, with regular boosters needed to keep people protected. In comparison, the immunity generated by a single vaccination against the ...
May 9, 2023
0
80
A new COVID variant XBB.1.16, or "Arcturus," has now been identified in at least 34 countries including the UK.
May 4, 2023
0
3
A new study by investigators from the Smidt Heart Institute at Cedars-Sinai suggests long COVID-19 might be caused by a dysfunction of the immune system.
Apr 27, 2023
0
5
A University of Colorado Anschutz Medical Campus research team has discovered that the immunoglobulin G (IgG) antibodies in the plasma of multiple sclerosis (MS) patients are toxic to neurons, a finding the lead investigator ...
Apr 26, 2023
0
81
An anonymous San Diego resident has become a fascinating example of how the human immune system fights SARS-CoV-2. In a new investigation, scientists from La Jolla Institute for Immunology (LJI) have shown how antibodies, ...
Apr 25, 2023
0
73
A new class of immunotherapy shows promising results for fighting the most aggressive form of skin cancer.
Apr 25, 2023
0
72
A treatment combining two antibodies against the coronavirus SARS-CoV-2 strongly protected high-risk people with early COVID-19 symptoms from hospitalization and death in an international Phase 2/3 clinical trial conducted ...
Apr 19, 2023
0
15
Scientists in Melbourne have designed a new type of oral capsule that could mean pain-free delivery of insulin and other protein drugs.
Apr 19, 2023
0
15
Is it possible to improve the antibodies that the body produces to fight SARS-CoV2? In a study led by researchers from Lund University in Sweden, this was investigated by redesigning antibodies and combining them against ...
Apr 18, 2023
0
108
With continuous mutations of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the severe immune escape of omicron subvariants highlights the need for development of next-generation broad-spectrum vaccines, especially ...
Apr 17, 2023
0
4
